Arcutis Biotherapeutics
ARQT
208 hedge funds and large institutions have $1.79B invested in Arcutis Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 60 increasing their positions, 65 reducing their positions, and 28 closing their positions.
107% more call options, than puts
Call options by funds: $8.22M | Put options by funds: $3.96M
75% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 28
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
50% more capital invested
Capital invested by funds: $1.2B → $1.79B (+$596M)
11% more funds holding
Funds holding: 188 → 208 (+20)
0.03% more ownership
Funds ownership: 110.05% → 110.08% (+0.03%)
8% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 65
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$28.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.5M |
| 3 |
CM
Cercano Management
Bellevue,
Washington
|
+$13.8M |
| 4 |
Millennium Management
New York
|
+$12.7M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$32.2M |
| 2 |
SC
Stempoint Capital
New York
|
-$14M |
| 3 |
PA
Perceptive Advisors
New York
|
-$12.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$10.3M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$9.64M |
ARQT Hedge Fund Activity: Q4 2024 in Review
208 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q4 2024, worth a combined $1.79B — up 50% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new ARQT positions and 28 closed out — a net gain of 21 holders — while 60 added to existing stakes and 65 trimmed.
The largest buyer was UBS Group, adding an estimated $28.2M. The largest seller was Citadel Advisors, cutting an estimated $32.2M.
- 208 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q4 2024, up from 188 in Q3 2024.
- Funds reported $1.79B of Arcutis Biotherapeutics stock for Q4 2024, up 50% quarter-over-quarter.
- 49 funds opened new Arcutis Biotherapeutics positions in Q4 2024 and 28 closed out, a net change of +21 holders.
- The largest Arcutis Biotherapeutics buyer in Q4 2024 was UBS Group, an estimated $28.2M added.
- The largest Arcutis Biotherapeutics seller in Q4 2024 was Citadel Advisors, an estimated $32.2M sold.
Based on aggregated 13F filings for Q4 2024.